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Re cent l y, we report e d that 6R-L-erythro-tetrahydrobiopterin 
( 6R-BH4 ), a natural cofactor for L-aromatic amino acid hydroxy-
lases, enhances in vivo releas e of acetylcholine (ACh) in the 
rat hippocampus: the enhancement was abolished after depletion of 
brain catecholamines and 5-hydroxytryptamine (5-HT) by pretreat-
ment with reserpine. In the preserrt study, we have used in vivo 
brain microdialysis to clarify the neuronal mechanism involved in 
th e enhancement of ACh release by 6R-BH 4 . After depletion of 
catecholamines by pretreatment of rats with a-methyl-p-tyrosine, 
6R-BH4 added to the perfusion fluid still induced an increase in 
extracellular ACh levels monitored by microdialysis as an index 
of ACh releas e . In contrast, after depletion of 5 - HT by pretreat-
ment with p-chlorophenylalanine, most of the 6R-BH4 -induced en-
hancement was eliminated. Exog e nous 5-HT and dopamine (DA) but 
not noradrenaline added to the perfusion fluid stimu lated ACh re-
lease with 5-HT being far more potent. Intraper i t oneal adminis-
tration of 5-hydroxytryptophan and L-DOPA also enhanced ACh re-
lease, presumably by their conversion to 5-HT and catecholamines, 
respectively. Administration of 6R-BH 4 increased h i ppocampal 5 -
HT release, as indicated by increased extracellular levels of the 
major 5-HT metabolite, 5-hydroxyindoleacetic acid . These results 
suggest that 6R-BH4 stimulates ACh release in the hippocampus, 
mainly by augmenting release of 5-HT, a potent stimulator of ACh 
release , and partly by augmenting release of DA . 
INTRODUCTIO 
6R-L-erythro-5,6,7,8 - Te t r ahydr o b iop te rin (6R - BH 4 ) is a 
. 6 . 21 d t t "~-- a n 16 natural cofactor for phenylalan l n e , t yr o slne an r y p o p11 
hydroxylases . Th e distribution o f 6R-BH 4 in th e brain i s po si -
tively correlated with th e acti vi ti e s of tyrosin e and tr ypto pha n 
hydroxylases 1 · 14 · 15 . In addition, '"thes e hydroxylases s eem t o b e 
unsaturated with tissue levels of 6R-EH 4 , since its adminis t ra -
tion enhances the synthesis of brain catecholamines10 · 18 and 5-
hydroxytryptamine (5-HT) 18 · 27 . Thus, 6R-BH4 has been consid e r e d 
to play an important role in regulation of neurotransmitter 
monoamine biosynthesis . 
In our recent reports using in vivo brain microdialysis, 
administration of 6R-BH4 was found to enhance in vivo releas e of 
dopamine (DA)ll , l 7 and 5-HT1 7 in the striatum of rats; it also 
enhanced the releas e of acetylcholine (ACh) in the hippocam-
pus23·24 , and of glutamate in the striatum and frontal cort e x 17 . 
Furthermore, the enhanced release of glutamate in the stria t um b y 
6R-BH4 was shown to be mediated by the DAergic neuronal system, 
since it was abolished after destruction of striatal DAergic 
nerve terminals by intrastriatal injection of 6-hydroxydopa -
mine 17 . Similarly, enhancement of ACh release in the hippocampus 
seems to be mediated by monoaminergic neuronal systems, since it 
was abolished after depletion of both catecholamines and 5-HT by 
reserpine 23 . 
However, since reserpine is known to deplete both catechol-
2 3 
amines and 5-HT30 
' 
it is presently unknown which of these 
monoaminergic systems (catecholaminergic, 5-HTergic or both) is 
involved in the enhancement of ACh release by 6R-BH4 . It is also 
unknown whether the involved monoaminergic system is activated or 
depressed by 6R-BH 4 and what effects (stimulatory or inhibitory) 
on ACh release the monoamine neurotransmitters exert. To clarify 
these points, the effects of 6R-BH4 on ACh release were examined 
following selective depletion of catecholamines or 5-HT . The 
effects of rnonoamines themselves and their precursors, such as 5-
hydroxytryptophan (5-HTP) and L-DOPA administration on ACh 
release were also examined . Finally, the effects of 6R-BH4 on 
release of monoamines were examined. 
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MATERIALS AND METHODS 
Brain microdialysis 
Male Wistar rats weighing 250-300 g were lightly anesthe-
tized with diethyl ether and mounted on a stereotaxic apparatus 
(incisor bar 3.3 mm below the auricular horizontal plane). The 
skull was exposed by a midline skin , incision and a burr hole of 3 
mm diameter was drilled. A U-shaped probe for microdialysis (BDP 
23-03, EICOM, Kyoto, Japan) was stereotactically implanted into 
the right hippocampus (coordinates taken from the bregma with the 
skull flat : A, -5 . 8; L, 5 . 0; V, -6 . 8 mm, from the Atlas of 
Paxinos and Watson 25 ) and fixed in place with cranioplastic 
cement . After the rats had recovered from the anesthesia, brain 
microdialysis was carried out under freely-moving condi-
tions11·12·22-24 . The dialysis probe was continuously perfused 
at a flow rate of 5.4 #l/rnin with Ringer solution (147 mM aCl, 
2 . 3 mM CaCl 2 and 2 . 3 mM KCl; pH 6.1) containing 30 ¥M physostig-
mine sulfate, an inhibitor of acetylcholinesterase, and the dial-
ysates were collected every 20 min. Unless otherwise specified, 
dialysates were directly injected onto HPLC for analysis of ACh 
without purification. 
Immediately before use, 6R - BH4 dihydrochloride, noradrena-
line (NA) bitartrate , DA hydrochloride or 5-HT creatinine sulfate 
was dissolved in the perfusion fluid to the desired concentra-
tion : the final pH of the solution was adjusted to that of Ringer 
solution (6 . 1) with 20 mM NaOH . 
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Purification of ACh using Sephadex G-10 columns 
In experiments, where 6R-BH 4 was added to the perfusion 
fluid, ACh recovered in dialysates was analyzed after purifica-
tion on small columns of Sephadex G-10 (Pharmacia, Uppsala, 
'")3 Sweden), as described recently~ . In brief, total amount of the 
hippocampal dialysate was applj_ed onto the Sephadex G-10 column 
(bed volume, 7 x 60 mm), which had been equilibrated with 10 mM 
HCOOH. After the column was washed with 1.0 ml of 10 mM HCOOH, 
the next 1-ml fraction of 10 ~~ HCOOH was collected, lyophilized 
to dryness, and reconstituted in 120 #l of distilled water . An 
aliquot (75 #l) of the solution was injected onto HPLC for 
analysis of ACh. 
Determination of ACh in dialysates 
ACh in crude dialysates or in eluates from Sephadex G-10 
columns was determined using HPLC with an immobilized enzyme 
reactor and an electrochemical detector as described recent-
ly8,12,22-24. The HPLC system consisted of a Hitachi (Tokyo, 
Japan) L-6000 pump, a Hitachi 655A-40 automated sample injector, 
a separation column of polystyrene resin (Eicompak AC-Gel, 6 x 
300 mm; EICOM, Kyoto, Japan), an enzyme reactor (containing 
acetylcholinesterase and choline oxidase) and an electrochemical 
detector (Eicom Model 100) with a working electrode of platinum. 
The potential of the electrochemical detector was set at +450 mV. 
The mobile phase was 100 mM sodium phosphate buffer (pH 8.0) 
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containing 300 mg/L sodium 1-decanesulfonate and 90 mg/L 
tetramethylammonium chloride, and was pumped at a flow rate of 
1.0 ml/min. Quantification of ACh and choline was performed by 
comparison with peak heights of known amounts of authentic 
standards. 
Purification and analysis of ACh in·e dialysates using ~ column-
switching HPLC system 
In experiments, where NA, DA and 5-HT were directly added to 
the per1usion fluid, ACh in dialysates was purified and analyzed 
using a column-switching HPLC method, as described recently 22 . 
In this system, a short column of polystyrene (called "isolation 
column" vs . separation column) and the second pump were added to 
the above-mentioned standard HPLC system for ACh analysis, to 
remove these monoarnines from the samples. The isolation column 
was located on the upstream of the separation column through a 
switching valve . 
For analysis , the dialysate sample containing monoamines was 
directly injected onto the HPLC system. When choline and ACh in 
the sample had been eluted from the isolation column but mono-
amines were still retained on the column, the position of the 
switching valve was changed so that the isolation column was 
isolated from the main route. After this switching, the isola-
tion column was washed with the mobile phase driven by the second 
pump through the switching valve, to elute the monoamines still 
retained on the column out of the system: the main column 
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continued to be perfused with the mobile phase from the main 
pump. As a result, the earlier eluate from the isolation column, 
which contained ACh and choline but not monoamines, was advanced 
to the main column for a subsequent analysis. After both analy-
sis of choline and ACh and washing of the isolation column had 
been completed, the switching valve was restored to the initial 
position and the next injection of the dialysate was performed . 
The mobile phase was the same as that for the standard ACh 
analysis system, which was delivered at flow rates of 1 . 0 ml/min 
and 2 . 0 ml/min with the main pump and the subsidiary pump, respec-
tively . 
Determination of monoamines in dialysates and in tissue extracts 
In some experiments, the contents of A, DA and 5-HT in ho-
mogenates of the hippocampus and the rest of the whole brain was 
simultaneously determined, using HPLC with electrochemical 
detection13 · 18 - 20 · 23 · 24 · 29 . That is, the hippocampus and the 
rest of the whole brain were homogenized in 1 ml and 10 ml, 
respectively, of 0 . 1 M perchloric acid containing 1 mg/ml sodium 
bisulfite and 1 mM EDTA, and the homogenate was centrifuged at 
17,500 x g for 15 min at 4°C. The resulting supernatant was 
passed through a membrane filter (pore size, 0.45 ~M), and an 
aliquot of the filtrate was injected onto HPLC with electro-
chemical detection. The mobile phase was 100 mM citrate/sodium 
acetate buffer (pH 3.8) containing 15% methanol, 1 0 0 ~M EDTA and 
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15Q mg/L sodium-1-octanesulfonate, which was pumped at a flow 
rate of 1.0 ml/min. A 5C18 reverse-phase column (Cosmosil, 4.6 x 
150 mm; Nacalai Tesque, Kyoto, Japan) was used for separation. 
The working electrode of the electrochemical detector was of 
graphite carbon, and its potential was set at +700 mV against th e 
Ag/AgCl reference electrode. 
NA and DA in dialysates were analyzed after purification 
with a small-scale alumina batch method, using HPLC with electro-
chemical detection, as described elsewhere11 . 5-HT, 5-hydroxy-
indoleacetic acid (5-HIAA), 3,4-dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) in dialysates were simulta -
neously analyzed using HPLC with electrochemical detection, as 
described recently3,4 . 
Procedures for monoamine depletion in the brain 
In some experiments, rats were treated with inhibitors of 
tyrosine hydroxylase (a-methyl-p-tyrosine, a-MT) or tryptophan 
hydroxylase (p-chlorophenylalanine, PCPA) to deplete catechol-
amines or 5-HT in the brain, respectively . a-MT was intra-
peritoneally injected three times (20 h, 4 h and 2 h) before 
experiments : the doses of the first , the second and the last 
injections were 200 mg/kg, 200 mg/kg and 100 mg/kg, respectively . 
PCPA was injected intraperitoneally 48 h before experiments at 
the dose of 400 mg/kg. 
Materials 
Reagents were obtained from the following sources : ACh 
9 
bromide, physostigmine sulfate, NA bitartate, DA hydrochloride 
5-HT creatinine sulfate and 5-HIAA from Wako Pure Chemical 
Industries, Osaka, Japan; sodium 1-decanesulfonate and sodium 1-
octanesulfonate from Tokyo Kasei Kogyo, Tokyo, Japan; PCPA and 
MT from Sigma, St. Louis, U.S.A. 6R-BH4 dihydrochloride was a 




All results were expressed as means~ S.E.M. The data were 
subjected to a two-way analysis of variance, and when significant 
F values were encountered, Neumann-Keuls' multiple-range test was 
used to test for significant differences between treatment 
means
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As described recently 23 , ACh levels in dialysates increased 
in a concentration-dependent manner following infusion of various 
concentrations of 6R-BH4 and reached the maximum in the fraction 
collected between 20 and 40 min: the maximal level was 6-fold of 
the basal level at a final concentration of 1 mM (Fig. 1A). 
When 6R-BH4 was given after pretreatment with a-MT, a selec-
tive inhibitor of tyrosine hydroxylase, it increased the ACh 
levels to the same extent as in the absence of the pretreatment 
with a-MT (Fig. lB). In contrast, after pretreatment with PCPA, 
a selective inhibitor of tryptophan hydroxylase, the 6R-BH4 -
induced increase in ACh levels was reduced to about 20% of the 
value in the absence of the pretreatment with PCPA (Fig. 1C). 
Both a-MT and PCPA had little effect on basal ACh levels (Figs. 
1B and 1C) . 
Table 1 shows the effects of pretreatment with a-MT or PCPA 
on the contents of NA, DA and 5-HT in the hippocampus. After 
pretreatment with a-MT, the contents of A and DA in the hippo-
campus were reduced ·to 5 . 03% and 19.8% , respectively, of the 
control value, but the content of 5-HT in the hippocampus was 
virtually unchanged. After pretreatment with PCPA, the content 
of 5-HT in the hippocampus was reduced to 16.7% of the control 
value, but the contents of NA and DA were unaffected. Essential-
ly similar results were obtained for the rest of the brain (data 
not shown) . 
1 1 
We determined the effects of exogenous monoamines added to 
the perfusion fluid on ACh levels in dialysates (Fig. 2). 
Infusion of NA up to 5 mM in the perfusion fluid was without 
effect on ACh levels in dialysates. In contrast, infusion of DA 
or 5-HT increased ACh levels in dialysates in a concentration-
dependent manner: the maximal levels were approximately 200% of 
the basal level for DA and 400% for 5-HT. 
We also examined the effects of increases in endogenous 
monoamines on ACh levels in dialysates (Fig. 3). For this pur-
pose, ACh levels in dialysates were determined following admin-
istration of monoamine precursors, such as L-DOPA and 5-HTP. ACh 
levels in dialysates were unchanged following administration of 
50 and 100 mg/kg of L-DOPA. At 200 mg/kg of L-DOPA, the ACh 
levels significantly increased and reached the maximum (140% of 
the basal level) in the fraction collected between 40 and 60 min 
after the injection (Fig. 3A). In contrast, the effects of 
administration of 5-HTP were more marked. The ACh levels 
increased in a dose-dependent manner following administration of 
various doses of 5-HTP and reached the maximum in the fraction 
collected between 40 and 60 min after the injection: the maximal 
level was 285~o of the basal l 1 t 200 /k eve a mg g of 5-HTP (Fig. 3B) . 
In separate experiments, we determined the changes in the 
monoamine content in the brain following administration of L-DOPA 
or 5-HTP. That is, experiments were performed according to the 
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sam~ protocol as that in Fig. 3 except that the rats were killed 
60 min after the administration for determination of the 
monoamine content in the brain. Following administration of L-
DOPA, the contents of NA and DA in the hippocampus increased in a 
concentration-dependent manner and at 200 mg/kg, they were 134% 
and 285% of the control value, respectively (Table II). The 
content of 5-HT in the hippocampus was virtually unaffected by 
administration of L-DOPA . Administration of 5-HTP produced a 
dose-dependent increase in the content of 5-HT: the increases 
were 190, 280 and 540% of the control value, respectively, at the 
doses of 50, 100 and 200 mg/kg. Administration of 5-HTP had 
little effect on the contents of NA and DA in the hippocampus 
(Table II) . Essentially similar results were obtained for the 
rest of the brain (data not shown). 
Finally, to estimate the changes in in vivo release of DA 
and 5-HT following administration of 6R-BH 4 , we attempted to 
determine extracellular levels of DA and 5-HT in the hippocampus . 
However, both DA and 5-HT in dialysates were found to be undetec-
table (< 50 fmol/20 min-fraction) before and after administration 
of 6R-BH4 . Therefore , we measured extracellular levels of DA and 
5-HT metabolites as indices of release of these monoamines . DA 
metabolites such as DOPAC and HVA in dialysates were also undetec-
table (< 50 fmol/20 min-fraction) before and after administration 
of 6R-BH4 . In contrast, extracellular levels of 5-HIAA, a major 
5-HT metabolite, were found to increase to 150 % of the basal 
13 




6R-BH4 given through the dialysis membrane induced a marked 
increase in extracellular ACh levels monitored by in vivo brain 
microdialysis, an index of ACh release (Fig. lA), as reported re-
cently23. 
The 6R-BH4 -induced increase i~ACh release persisted after 
selective depletion of catecholamines by a-MT (Fig. lB and Table 
I). In contrast, the major portion of the increase was elimi-
nated after selective depletion of 5-HT by PCPA (Fig. lC and 
Table I) . These results suggest that the 5-HTergic system is 
mainly involved in the enhancement of ACh release by 6R-BH 4 . 
However, after pretreatment with PCPA, a minor portion (20%) of 
the 6R-BH4 -induced increase still remained. The PCPA-resistant 
increase could be mediated by the 5-HT , which had remained even 
after pretreatment with PCPA (Table I) . Alternatively, the 
increase might be mediated by catecholaminergic systems (DAergic 
and/or Aergic systems), considering the possibility that the 
catecholamine-mediated portion is too small to detect as a signif-
icant change (Fig . lB) . 
On the other hand, the basal extracellular levels of ACh 
were unchanged after pretreatment with a-MT or PCPA (Fig. 1). 
This result indicates that there is little, if any, tonic control 
of catecholamines and 5-HT under basal conditions . 
Exogenous 5-HT and DA (but not NA), added to the perfusion 
fluid, augmented ACh release with 5-HT being more potent than DA 
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(Fig. 2). Furthermore, an increase in release of endogenous 
catecholamines and 5-HT, which was expected to occur following 
administration of L-DOPA and 5-HTP, also enhanced ACh release 
with 5-HTP being more potent than L-DOPA (Fig. 3). These results 
taken together suggest that 5-HT and to a lesser extent, DA, 
which are released from monoaminergic nerve terminals, can 
stimulate ACh release in the hippocampus. At present, it is 
established that the hippocampus is innervated by the 5-HTergic 
and NAergic neurons as well as the cholinergic neurons 5 • 9 , but 
the DAergic innervation of the hippocampus is still controver-
sial. However, our data suggest that there is a minor DAergic 
projection to the cholinergic neurons in the hippocampus . Thus, 
combined with the results in Fig. 1, the present study strongly 
indicates that enhancement of ACh release by 6R-BH4 is mediated 
mainly by activation of 5-HTergic system, with a minor portion 
being contributed to by the DAergic system. 
In fact, an increase in extracellular levels of 5-HIAA, a 
metabolite of 5-HT, was observed following administration of 6R-
BH4 (Fig. 4). Since extracellular levels of 5-HIAA can be 
regarded as a good index of the rate of 5-HT release 2 · 7 , the 
present observation suggests that 6R-BH4 actually enhances 5-HT 
release in the hippocampus. This result is in good agreement 
with the previous reports that 6R-BH4 enhances 5-HT release in 
vivo in the rat striatum as monitored by brain microdialysis 17 
16 
and. high K+-evoked [ 3H]5-HT release from the superfused 
hippocampal slice in vitro31. 
There, however, seems to be quantitative discrepancy. 
is, administration of 6R-BH 4 to the perfusion fluid at 1 mM 
That 
(which is the supramaximal concentration) markedly increased ACh 
levels: the increase above the control value was 500% (Fig. l). 
On the other hand, the maximal increase by exogenous 5-HT or 5-
HTP is 250 - 300% above the control value, and that by exogenous 
DA or L-DOPA is 40 - 100% above the control value (Figs. 2 and 
3): the sum of these values amounts to only 290 ~ 400%, compared 
with the 500% increase for 6R-BH4 . This discrepancy might be 
explained by assuming that there is some synergism between the 5-
HTergic and DAergic systems, like that reported for D1 and D2 
receptors 26 . Alternatively, 6R-BH 4 alone might release 5-HT 
mainly into critical sites of the synapse to cholinergic neurons, 
which are surrounded by some diffusion barrier against exogenous-
ly administered 5-HT or 5-HTP-derived 5-HT. 
In summary, we showed that 6R-BH 4 enhances ACh release in 
the hippocampus, mainly by augmenting release of 5-HT, a potent 
stimulator of ACh release, and partly by augmenting release of DA. 
. 1 7 
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LEGENDS FOR FIGURES 
Fig. 1. Effects of infusion of 6R-BH 4 on extracellular ACh 
levels monitored by in vivo brain microdialysis in control rats 
and rats pretreated with a-MT or PCPA. One hundred min after 
the beginning of brain microdialys~_"s, 6R-BH 4 ( e ) was added to 
the perfusion fluid at a final concentration of 1 mM during 60 
min as indicated by black bars. The collected dialysate was 
injected onto HPLC with an elecrochemical detector after purifica-
tion with a Sephadex G-10 column. (A) Control rats (pretreated 
with vehicle alone); (B) a-MT-trea ·ted rats; (C) PCPA-pretreated 
rats. Open circles represent basal ACh levels in dialysates in 
the absence of infusion of 6R-BH4 . Each value is the mean + 
S.E.M. of 4 determinations. * p < 0.05; * * p < 0.01; 
significantly different from control. 
Fig. 2. Effects of exogenous NA, DA and 5-HT added to the 
perfusion fluid on ACh levels in dialysates . One hundred minutes 
after the beginning of the brain microdialysis, NA, DA and 5-HT 
was added to the perfusion fluid at the indicated concentrations . 
ACh collected in dialysate was purified and analyzed using a 
column-switching HPLC method. An open circle (control value) 
represents the mean of ACh levels in five fractions of dialysates 
before infusion of monoamines. Closed symbols represent the 
24 
maximal ACh levels attained during infusion of the indicated 
concentrations of monoamines. ,6. , A; • . DA; • . 5-HT. Each 
value is the mean~ S.E.M. of 4 determinations. 
significantly different from a control group. 
** P< 0.01, 
Fig. 3. Effects of administration of L-DOPA and 5-HTP on ACh 
levels in dialysates. One hundred minutes after the beginning of 
the brain microdialysis, rats were injected intraperitoneally 
with L-DOPA (A) or 5-HTP (B) at the indicated doses. ACh levels 
in dialysates were monitored up to 100 min after the injection. 
Open bars (control value) represent the mean of ACh levels in 
five fractions of dialysates before administration of L-DOPA and 
5-HTP. Closed bars represent the maximal ACh levels, which was 
attained in the third fraction (40 - 60 min) following injection 
of indicated doses of L-DOPA or 5-HTP. Each value is the mean + 
S.E . M. of 4 determinations . ** P< 0.01, significantly different 
from a control group. 
Fig. 4 . Effects of infusion of 6R-BH4 on 5-HIAA levels in 
dialysates. One hundred minutes after the beginning of brain 
microdialysis, 6R-BH 4 ( tt ) was added to the perfusion fluid at a 
final concentration of 1 mM during 60 min as indicated by a 























































Eff ects o f p re tr e atment with a-MT or PCPA on the contents of monoamine in t h e hippo-
campu s 
At t h e end of brain microdialysis experiments , rats were decapitated and the contents 
of NA , DA a n d 5-HT in the hippocampus were determined as described in Materials and 
Metho d s. 
Each value is th e mean + S.E.M. of 4 determinations. 
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(nmol/g tissue ) 
3 . 10 + 0.13 
** 0 . 156 + 0 . 095 




0 . 182 + 0 . 006 
** 0 . 036 + 0 . 001 
0 . 179 + 0 . 003 
5-Hydroxytryptamine 
(nmol / g tissue) 
1 . 26 + 0.051 
1. 28 + 0 . 06 1 
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Table II 
~ . 
Effects of administration of L-DOPA or 5-HTP on monoamine content in the hippocampus 
Each value is the mean + S.E.M. of 4 determinations. 
*, p< 0.05; **, p < 0.01; significantly different from the corresponding control 
values. 
Noradrenaline Dopamine 5-Hydroxytryptamine 
(nmol/g tissue) (nmol/g tissue) (nmol/g tissue) 
vehicle 3.06 + 0 . 1 7 0.185 + 0.008 1 . 2 6 :::+ 0 . 1 6 
-
-
L-DOPA, 50mg/kg 3 . 37 + 0.29 0.200 + 0.013 1.28 + 0.17 
- -
-












** 5-HTP, 100 mg/kg 3 . 00 + 0 . 28 0.177 + 0 .020 3.58 + 0 . 37 
- -
-
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